| Name | Title | Contact Details |
|---|---|---|
Brian Bearden |
Chief Operations Officer | Profile |
Ingersoll Rand Inc. (NYSE:IR), driven by an entrepreneurial spirit and ownership mindset, is dedicated to Making Life Better for our employees, customers, shareholders, and planet. Customers lean on us for exceptional performance and durability in mission-critical flow creation and industrial solutions. Supported by over 80+ respected brands, our products and services excel in the most complex and harsh conditions. Our employees develop customers for life through their daily commitment to expertise, productivity, and efficiency. For more information, visit www.IRCO.com.
Bradesco Bank is a Member FDIC Equal Housing Lender. With over 50 years of experience catering to the financial needs of individual, corporate and institutional customers, our products and services have been carefully structured to serve the domestic and international markets, which, combined with our personalized service, ensures that your experience with Bradesco Bank will be unparalleled. For more information, please access: http://www.bradescobank.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
ADB primarily provides specialized financial intermediation and related services with the objective of promoting a sustained and diversified agricultural and rural development as a foundation for the countrys over all development .In addition, to cultivate effective linkages between the agricultural sector and the rest of the economy and to complement the provision of banking services through out the country, ADB also provides ordinary commercial banking services , as well as servicing other sectors of the economy.